Telix Pharmaceuticals

Stories

Telix acquires isotope maker ITM in deal worth up to $2.35 billion

As of September 2026: Acquirer; listed on ASX and Nasdaq under ticker TLX

Telix Pharmaceuticals, an Australian maker of cancer imaging and treatment agents, agreed on September 21 to buy German isotope producer ITM Isotope Technologies Munich. The deal is worth up to $2.35 billion all-in, with $1.65 billion paid upfront, most of it in Telix shares.

Updated Sep 21

FDA approves Telix's Pixclara, first FET-PET imaging drug for glioma

New Capabilities

As of September 2026: Holds first FDA-approved FET-PET imaging drug for glioma

Brain cancer doctors face a maddening problem: after radiation and chemo, standard MRI scans often can't tell whether a suspicious spot is tumor regrowth or treatment-related change. The two scenarios call for opposite treatments. The FDA just approved a test that settles the question.

Updated Sep 15